Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
40 results about "Molecular mimicry" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Molecular mimicry is defined as the theoretical possibility that sequence similarities between foreign and self-peptides are sufficient to result in the cross-activation of autoreactive T or B cells by pathogen-derived peptides. Despite the prevalence of several peptide sequences which can be both foreign and self in nature, a single antibody or TCR (T cell receptor) can be activated by just a few crucial residues which stresses the importance of structural homology in the theory of molecular mimicry. Upon the activation of B or T cells, it is believed that these "peptide mimic" specific T or B cells can cross-react with self-epitopes, thus leading to tissue pathology (autoimmunity). Molecular mimicry is a phenomenon that has been just recently discovered as one of several ways in which autoimmunity can be evoked. A molecular mimicking event is, however, more than an epiphenomenon despite its low statistical probability of occurring and these events have serious implications in the onset of many human autoimmune disorders.
Nano antibody of anti-deoxynivalenol antibody
InactiveCN104592389AHave immune response propertiesGood effectImmunoglobulinsGenetic engineeringEpitopeEndurance capacity
The invention belongs to the technical field of biology and specifically relates to a preparation method and an application of a nano antibody capable of specially binding with an anti-deoxynivalenol antibody. The amino acid sequence of the nano antibody is SEQ ID No. 1. The invention also relates to a nucleotide for encoding amino acid. The nano antibody is capable of taking the place of the expensive high-toxicity DON standard substances, and can be applied to the immunological detection of the DON as a competitive antigen or a solid-phase envelope antigen; the nano antibody has immunoreaction characteristic similar to that of natural DON molecule, and is excellent in effect. Compared with the traditional antigen mimic epitopes based on polypeptides and the traditional anti-idiotype antibodies based on IgG, the nano antibody has the characteristics of more stable structure, acid-alkali resistance, high temperature resistance, high detection sensitivity and the like, and therefore, the immunodetection stability of the nano antibody is greatly improved, and meanwhile, the endurance capacity of the nano antibody to the environment is also improved.
Owner:NANCHANG UNIV
Combinant polypeptide for use in the manufacture of vaccines against Campylobacter induced diarrhea and to reduce colonization
This invention comprises a recombinant protein comprising the maltose binding protein (MBP) of Escherichia coli fused to amino acids 5–337 of the FlaA flagellin of Campylobacter coli VC167 which has provided evidence of immunogenicity and protective efficacy against challenge by a heterologous strain of campylobacter, Campylobacter jejuni 81–176 in mammals. The invention further comprises a recombinant DNA construct encoding the immunodominant region (region I through III) of flagellin from Campylobacter spp. for use as a component of a vaccine against Campylobacter diarrhea. The invention therefore represents an effective treatment against Campylobacter but avoids inducing the autoimmune Guillain Barre Syndrome (GBS), a post-infection polyneuropathy caused by Campylobacter molecular mimicry of human gangliosides which has hampered the development of vaccines heretofore.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY
Detection, characterization and treatment of viral infection and methods thereof
InactiveUS7572621B2High sensitivityStrong specificityMicrobiological testing/measurementImmunoglobulins against virusesIn vivoViral infection
Owner:CANADIAN BLOOD SERVICES
Cry1Ab toxin simulated antigen based on anti-idiotype nanometer antibody and application thereof
ActiveCN108101970AAvoid makingAvoid complexityBacteriaImmunoglobulins against bacteriaAntiendomysial antibodiesNucleotide
The invention belongs to the technical field of gene engineering antibodies and food biology, and relates to a Cry1Ab toxin simulated antigen based on an anti-idiotype nanometer antibody and application thereof. The amino acid sequence of the Cry1Ab toxin simulated antigen is shown as SEQ ID NO.1; the nucleotide sequence for coding the amino acid is shown as SEQ ID NO.9. The provided Cry1Ab toxinsimulated antigen can replace an expensive Cry1Ab standard product with the toxicity, and can be used as a competition antigen to be applied to competitive immunological detection of Cry1Ab; the immunoreaction characteristics similar to Cry1Ab molecules are realized; the effect is good.
Owner:JIANGSU ACAD OF AGRI SCI
Construction method and application of three-dimensional quantitative structure-activity relationship model of bcl-2 protein inhibitor
InactiveCN102262715APredicted binding constantFast Prediction of Binding ConstantsSpecial data processing applicationsEntity–relationship modelHigh-Throughput Screening Methods
The invention relates to a method for constructing a three-dimensional quantitative structure activity relationship model of a B-cell lymphoma-2 (Bcl-2) protein inhibitor and application of the method and belongs to the technical field of biological information. The method comprises the following steps of: according to the known small molecule inhibitor, establishing the three-dimensional quantitative structure activity relationship model of the Bcl-2 protein inhibitor by using a three-dimensional quantitative structure activity relationship technology; and further improving the accuracy of the model by using technologies for analyzing molecular similarity, optimizing molecular conformation, optimizing parameters and the like. By the invention, the Bcl-2 protein binding constants of an active unknown compound can be quickly predicted, and clues of the active compound are acquired within short time. Compared with the conventional high-throughput screening technology, the invention has the advantages of greatly improving screening efficiency and reducing cost.
Owner:SHANDONG UNIV
Detection, characterization and treatment of viral infection and methods thereof
InactiveUS20060115875A1High sensitivityStrong specificityMicrobiological testing/measurementImmunoglobulins against virusesIn vivoViral infection
A method of detecting, characterizing and treating viral infection is provided. In particular, a strategy of molecular mimicry is provided for characterizing viral behavior and / or a predisposition for a given viral outcome in vivo. Novel compositions are also provided for detecting, characterizing and treating viral infections.
Owner:CANADIAN BLOOD SERVICES
Nano antibody-based deoxynivalenol mimic antigen and application thereof
ActiveCN104311643AHave immune response propertiesGood effectDepsipeptidesBiological testingEndurance capacityNucleotide
The invention belongs to the biotechnical field and relates to nano antibody-based deoxynivalenol mimic antigen and application thereof. The amino acid sequence is shown in SEQIDNO:1. The invention further relates to nucleotide which codes the amino acid. The nano antibody-based deoxynivalenol mimic antigen provided by the invention can be used for replacing a DON (deoxynivalenol) standard substance which is high in price and strong in toxicity and is used as competitive antigen or solid phase coated antigen which is applied to immunological detection of DON. The mimic antigen has an immunoreaction characteristic which is similar to that of a natural DON molecule and is good in effect. Compared with conventional polypeptide-based antigen mimic epitopes and IgG-based conventional anti-idiotype antibody, VHH has the characteristics of being more stable in structure, resistant to acid and base and high temperature, high in detection sensitivity and the like. Therefore, the immunodetection stability is extremely enhanced, and meanwhile, the endurance capacity on the environment is further enhanced.
Owner:NANCHANG UNIV
Enrofloxacin-mimic antigen epitope peptide, and preparation method and application thereof
ActiveCN108387740AStrong drug resistanceThe test result is accurateMaterial analysis by observing effect on chemical indicatorBiological testingMimotopeImmunosorbent method
The invention provides an enrofloxacin-mimic antigen epitope peptide, and preparation methods and an application thereof. The ENR-mimic antigen epitope peptide having a sequence represented by GKPYITWis panned from a phage random display heptapeptide library through a phage display peptide library technology with an anti-ENR monoclonal antibody as a target. The invention respectively provides a method for preparing the antigen-mimic epitope by a phage amplification technology and a method for preparing the antigen-mimic epitope by a gene recombination technology. A concrete detection method is designed based on enzyme linked immunosorbent assay, colloidal gold immunochromatography and fluorescence microsphere immunochromatography by using the immunological binding property of the antigen-mimic epitope. The antigen-mimic epitope has similar immunoreactivity characteristics to natural ENR molecules, can be used in the immunological detection of ENR to replace an ENR standard substance having strong drug resistance and high price, and the detection result is accurate and highly-sensitive.
Owner:INST OF MICROBIOLOGY JIANGXI ACADEMY OF SCI
Preparation and application of nano antibody capable of specifically combining with anti-zearalenone antibody
ActiveCN105218675AHave immune response propertiesGood effectImmunoglobulinsBiological testingEpitopeNucleotide
The invention belongs to the biological technical field, and in particular to preparation and application of nano antibody capable of specifically combining with anti-zearalenone antibody and with an amino acid sequence of SEQ ID No.1; and the invention also relates to the nucleotides encoding the amino acid. The nano antibody of the invention can replace the expensive toxic Zen standard, and can be used in immunological detection of Zen as a competitive antigen or solid coating antigen. The nano antibody has similar immunological properties to natural Zen molecule, and good effect. Compared to a traditional antigen mimicking epitope based on polypeptide and a traditional anti-idiotype antibody based on IgG, the nano antibody has the advantages of more stable structure, acid resistance, alkali resistance, high temperature resistance and high detection sensitivity, so that the immune detection stability has been greatly improved, and the tolerance on the environment has also been improved.
Owner:NANCHANG UNIV
Deoxynivalenol mimetic antigen based on nanobody and its application
ActiveCN104311643BHigh detection sensitivityHas acid and alkali resistance and heat resistanceDepsipeptidesBiological testingNucleotideImmuno detection
Owner:NANCHANG UNIV
Atom site based flow velocity calculating method for molecular mimicry
InactiveCN104809361AStatistically accurateEliminate errorsSpecial data processing applicationsThermal motionTraffic volume
The invention relates to an atom site based flow velocity calculating method for molecular mimicry and belongs to the technical field of molecular mimicry. The method comprises the steps of accurately counting the number of atoms of flow penetrating through the cross section of a flow passage in molecular mimicry, and then, accurately calculating flow velocity. According to the atom site based flow velocity calculating method for molecular mimicry, provided by the invention, the flow velocity can be accurately calculated, and errors resulting from thermal motion velocity when the flow velocity is on an average according to molecular velocity in classical molecular mimicry are eliminated; the atom site based flow velocity calculating method is particularly applicable to low-speed flow, and the accuracy of calculation of the flow velocity can be greatly improved.
Owner:CHONGQING UNIV
Antigen mimic epitope of ochratoxin A and application thereof
InactiveCN103145808AGood effectHave immune response propertiesMicroorganism based processesPeptidesEpitopeOchratoxin A
The invention belongs to the technical field of biology, and relates to an antigen mimic epitope of ochratoxin A. The amino acid sequence of the antigen mimic epitope is as follows: KLGFQLHQPSWP, FNLHQPIHNWPL, AQFFQLHSQAYS or DGFQLHTPFSAK. The OTA (Ochratoxin A) antigen mimic epitope provided by the invention can replace an OTA standard product which is high in price and strong in toxicity and is applied to immunological detection on the OTA as a competitive antigen or a solid-phase envelope antigen; sf the antigen mimic epitope has immunoreaction characteristics similar to that of natural OTA molecules, and is very good in effect. The damage of the OTA to the human body health is reduced, the cost is saved, and high application values are provided.
Owner:NANCHANG UNIV
Antigen mimic epitope capable of mimicking fumonisins B1 and application of antigen mimic epitope
The invention belongs to the field of biotechnologies, and relates to an antigen mimic epitope capable of mimicking fumonisins B1. An amino acid sequence of the antigen mimic epitope is IHQELRYTKDSP. The antigen mimic epitope of FB1 is capable of replacing an FB1 standard substance which is high in price and strong in toxicity, and is applied to immunological detection of the FB1 as a competition antigen or solid-phase envelope antigen. The antigen mimic epitope has an immunoreaction characteristic similar to a natural FB1 molecule, and a good effect. The damage of the FB1 to the health of a human body is reduced, the cost is saved, and high application value is achieved.
Owner:NANCHANG UNIV
Drug virtual screening method and device based on molecular similarity and semi-supervised learning
ActiveCN113192572AImprove performanceGood practical engineering application valueMolecular designCheminformatics data warehousingData setPharmaceutical drug
The invention discloses a drug virtual screening method and device based on molecular similarity and semi-supervised learning. The method comprises the following steps: S1, collecting a data set to obtain a ligand molecule sample with a biological activity value and a ligand molecule sample without a biological activity value; s2, constructing a regression model by using the ligand molecule sample with the biological activity value obtained in the step S1; s3, calculating the similarity between molecules in the data set; s4, calculating triple loss by utilizing the molecular similarity obtained in the step S3 and the regression model obtained in the step S2; and S5, training the model according to the loss functions obtained in the steps S2 and S4. On the basis of a semi-supervised learning method, a large number of samples without experimental biological activity values are introduced into model training, model prediction values of the samples without the experimental biological activity values are constrained by using molecular similarity and triple loss, and the problem that a large number of samples without the biological activity values cannot effectively participate in model training in an actual application scene is solved.
Owner:NANJING UNIV OF POSTS & TELECOMM
Diethylstilbestrol mimic antigenic epitope peptide, and preparation method and application thereof
ActiveCN108358996AHarm reductionThe test result is accurateVector-based foreign material introductionPolypeptide with MBP-tagDiethylstilbestrolImmune reaction
The invention provides a diethylstilbestrol (DES) mimic antigenic epitope peptide, and a preparation method and an application thereof. Firstly, based on a phage display peptide library technology, ananti-DES monoclonal antibody is used as a target, and a DES antigen mimic epitope having the sequence of YVYPQQK, YVYPPGP or YVYPQSR is selected from a phage random display heptapeptide library. Centering on immune binding characteristics of the antigen mimic epitope, a specific detection method is designed based on enzyme-linked immunosorbent assay, colloidal gold immunochromatography and fluorescent microsphere immunochromatography. The antigenic mimic epitope has similar immunoreactivity characteristics to those of natural DES molecules, can replace an expensive DES standard substance having teratogenic and carcinogenic effects to be used in immunological detection of DES; the detection results are accurate and the sensitivity is high. The harm to human body health in the DES detectionprocess is effectively reduced, and meanwhile, the cost is saved.
Owner:INST OF MICROBIOLOGY JIANGXI ACADEMY OF SCI
Antigen mimic epitope capable of mimicking fumonisins B1 and application of antigen mimic epitope
The invention belongs to the field of biotechnologies, and relates to an antigen mimic epitope capable of mimicking fumonisins B1. An amino acid sequence of the antigen mimic epitope is TTLQMRSEMADD. The antigen mimic epitope of FB1 is capable of replacing an FB1 standard substance which is high in price and strong in toxicity, and is applied to immunological detection of the FB1 as a competition antigen or solid-phase envelope antigen. The antigen mimic epitope has an immunoreaction characteristic similar to a natural FB1 molecule, and a good effect. The damage of the FB1 to the health of a human body is reduced, the cost is saved, and high application value is achieved.
Owner:NANCHANG UNIV
A mimetic fumonisin b 1 Antigen mimotope and its use
Owner:NANCHANG UNIV
Dodecapeptide antigen mimic epitope for FB1 (fumonisins B1) and application of dodecapeptide antigen mimic epitope
The invention belongs to the field of biotechnologies and relates to a dodecapeptide antigen mimic epitope for FB1 (fumonisins B1). The amino acid sequence of the dodecapeptide antigen mimic epitope is SMLNDYRDYTTH. The FB1 antigen mimic epitope can substitute for an FB1 standard substance which is expensive and high in toxicity, can serve as a competitive antigen or a solid-phase coating antigen to be applied to immunological detection of the FB1, has immunoreaction characteristics similar to those of natural FB1 molecules and is very good in effect. The harm caused by the FB1 to human health is reduced, the cost is saved, and the dodecapeptide antigen mimic epitope has the very high application value.
Owner:NANCHANG UNIV
A kind of epitope peptide simulating dienestrol, its preparation method and application
ActiveCN108373495BHarm reductionThe test result is accurateVector-based foreign material introductionPolypeptide with MBP-tagDienestrolElisa method
The invention provides an epitope peptide simulating dienestrol, its preparation method and application. The technical solution is firstly based on the phage display peptide library technology, with the anti-DIS monoclonal antibody as the target, and panning from the phage random display heptapeptide library to obtain a DIS antigen mimic epitope whose sequence is CTLNWAC. The present invention respectively provides methods for preparing the antigen mimetic epitope by means of phage amplification and gene recombination. The present invention designs specific detection methods based on enzyme-linked immunosorbent assay, colloidal gold immunochromatography and fluorescent microsphere immunochromatography around the immunological binding characteristics of the antigen mimic epitope. The antigen mimic epitope has similar immune response characteristics to the natural DIS molecule, and can replace the expensive DIS standard substance with teratogenic and carcinogenic effects for the immunological detection of DIS, with accurate detection results and high sensitivity.
Owner:INST OF MICROBIOLOGY JIANGXI ACADEMY OF SCI
a fumonisin b 1 Dodecapeptide Antigen Mimotope and Its Application
Owner:NANCHANG UNIV
Cry1ab toxin mimetic antigen based on anti-idiotypic nanobody and its application
ActiveCN108101970BAvoid makingAvoid complexityBacteriaImmunoglobulins against bacteriaAntigenNucleotide
The invention belongs to the field of genetic engineering antibody and food biotechnology, and relates to a Cry1Ab toxin mimic antigen based on an anti-idiotype nanobody and its application. The amino acid sequence of the Cry1Ab toxin mimic antigen is shown in SEQ ID NO.1, and the nucleoside encoding the amino acid The acid sequence is as described in SEQ ID NO.9, and the Cry1Ab mimic antigen provided by the present invention can replace the expensive and toxic Cry1Ab standard product, and is used as a competitive antigen in the competitive immunological detection of Cry1Ab, which has a molecular similarity to Cry1Ab Immune response properties, good results.
Owner:JIANGSU ACAD OF AGRI SCI
Method to identify key markers of human pluripotent cell-derived somatic cells that predict molecular similarity to in vivo target cells
ActiveUS11359242B2Microbiological testing/measurementUnknown materialsPluripotential stem cellEmbryogenesis
Modeling Amyotrophic Lateral Sclerosis (ALS) with human induced pluripotent stem cells (iPSCs) aims to reenact embryogenesis, maturation, and aging of spinal motor neurons (spMNs) in vitro. As the maturity of spMNs grown in vitro compared to spMNs in vivo remains largely unaddressed, it is unclear to what extent this in vitro system captures critical aspects of spMN development and molecular signatures associated with ALS. Here, the Inventors compared transcriptomes among iPSC-derived spMNs, fetal, and adult spinal tissues. The Inventors resolved gene networks and pathways associated with spMN maturation and aging. These networks enriched for familial ALS genetic variants and were affected in sporadic ALS. Altogether, the Inventors' findings suggest that developing strategies to further mature and age iPSC-derived spMNs will provide more effective iPSC models of ALS.
Owner:CEDARS SINAI MEDICAL CENT
Antigenic epitope peptide imitating enrofloxacin, its preparation method and application
ActiveCN108387740BHave immune response propertiesHarm reductionMaterial analysis by observing effect on chemical indicatorPeptidesElisa methodImmunoresponse
The invention provides an enrofloxacin-mimic antigen epitope peptide, and preparation methods and an application thereof. The ENR-mimic antigen epitope peptide having a sequence represented by GKPYITWis panned from a phage random display heptapeptide library through a phage display peptide library technology with an anti-ENR monoclonal antibody as a target. The invention respectively provides a method for preparing the antigen-mimic epitope by a phage amplification technology and a method for preparing the antigen-mimic epitope by a gene recombination technology. A concrete detection method is designed based on enzyme linked immunosorbent assay, colloidal gold immunochromatography and fluorescence microsphere immunochromatography by using the immunological binding property of the antigen-mimic epitope. The antigen-mimic epitope has similar immunoreactivity characteristics to natural ENR molecules, can be used in the immunological detection of ENR to replace an ENR standard substance having strong drug resistance and high price, and the detection result is accurate and highly-sensitive.
Owner:INST OF MICROBIOLOGY JIANGXI ACADEMY OF SCI
Antigenic mimic epitope of fumonisin B1 and application thereof
The invention belongs to the technical field of biology, and relates to an antigenic mimic epitope of fumonisin B1 (FB1). The antigenic mimic epitope has the amino acid sequence as follows: NNAAMYSEMATD, FYTSPGRTSHYM, IHQELRYTKDSP, GDGVHKSHDIRG, TTLQMRSEMADD, SMLNDYRDYTTH or TRDKSSMLERWP. The FB1 antigenic mimic epitope can be used for replacing a standard FB1 with expensive price and strong toxicity, and can be used as a competitive antigen or a solid-phase enveloped antigen applied to the immunological detection of the FB1. The immunoreaction characteristic of the antigenic mimic epitope is similar to that of a natural FB1 molecule, i.e., the effect of the antigenic mimic epitope is very good. In addition, the antigenic mimic epitope also has advantages that the harm of the FB1 to human health is reduced and the cost is saved, so that the application value is relatively high.
Owner:NANCHANG UNIV
Mimic fumonisin b 1 Antigen mimotope and its application
Owner:NANCHANG UNIV
Antigenic mimic epitope of aflatoxin (AF) B1 and application thereof
InactiveCN103059101BHarm reductionHave immune response propertiesPeptidesBiological testingAflatoxin BHuman health
The invention belongs to the field of biotechnology and relates to an antigenic mimic epitope of aflatoxin B1. The amino acid sequence of the antigenic mimic epitope is CDPRKHIHC or VPYSPHYFERMI. The antigenic mimic epitope of aflatoxin B1 can replace an expensive AFB1 standard substance with strong toxicity and be applied to an immunological detection of AFB1 as a competitive antigen or a solid phase envelope antigen. The antigenic mimic epitope has immunoreaction characteristics similar to natural AFB1 molecules, and has good effects. Harm to human health caused by AFB1 is reduced, the cost is saved, and the antigenic mimic epitope of AFB1 has great application value.
Owner:NANCHANG UNIV
GPU parallel computing molecular similarity method, device and system and medium
PendingCN114520022AEasy to overlapCalculation speedResource allocationOther databases queryingMolecular mimicryMolecular Bank
The invention discloses a GPU (Graphics Processing Unit) parallel computing molecular similarity method, device and system and a medium. The method comprises the following steps of: inputting a query compound; calculating the center of mass of the query compound; translating and / or rotating the query compound based on the center of mass; parallel computing is carried out through a GPU, and query compounds before and after transformation serve as initial search points to be compared with molecular compounds in a molecular library; and filtering according to a comparison calculation result, and outputting a molecular compound similar to the query compound.
Owner:深圳北鲲云计算有限公司
Antigen mimotope against ochratoxin a and its application
InactiveCN104530194BGood effectHave immune response propertiesPeptidesBiological testingMimotopeToxin
Owner:NANCHANG UNIV
Antigenic mimic epitope of aflatoxin (AF) B1 and application thereof
InactiveCN103059101AHave immune response propertiesHarm reductionPeptidesBiological testingHuman healthMimotope
The invention belongs to the field of biotechnology and relates to an antigenic mimic epitope of aflatoxin B1. The amino acid sequence of the antigenic mimic epitope is CDPRKHIHC. The antigenic mimic epitope of aflatoxin B1 can replace an expensive AFB1 standard substance with strong toxicity and be applied to an immunological detection of AFB1 as a competitive antigen or a solid phase envelope antigen. The antigenic mimic epitope has immunoreaction characteristics similar to natural AFB1 molecules, and has good effects. Harm to human health caused by AFB1 is reduced, the cost is saved, and the antigenic mimic epitope of AFB1 has great application value.
Owner:NANCHANG UNIV
can mimic fumonisin b 1 Antigen mimotope and its application
The invention belongs to the field of biotechnologies, and relates to an antigen mimic epitope capable of mimicking fumonisins B1. An amino acid sequence of the antigen mimic epitope is TRDKSSMLERWP. The antigen mimic epitope of FB1 is capable of replacing an FB1 standard substance which is high in price and strong in toxicity, and is applied to immunological detection of the FB1 as a competition antigen or solid-phase envelope antigen. The antigen mimic epitope has an immunoreaction characteristic similar to a natural FB1 molecule, and a good effect. The damage of the FB1 to the health of a human body is reduced, the cost is saved, and high application value is achieved.
Owner:NANCHANG UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com